Details

Perspectives on the impact of regulatory measures on national COVID-19 vaccination programs: a qualitative study from six EU member states
ID Vliet, Ella van (Author), ID Kos, Mitja (Author), ID Čebron Lipovec, Nanča (Author), ID Leonardo Alves, Teresa (Author), et al.

.pdfPDF - Presentation file, Download (438,68 KB)
MD5: 1F118BB816EB230C0C9B10804FB5F7A6
URLURL - Source URL, Visit https://www.tandfonline.com/doi/full/10.1080/20523211.2025.2576620 This link opens in a new window

Abstract
Background: The European Medicines Agency (EMA) issued regulatory recommendations and communications in 2021 about the risk of thrombosis with thrombocytopenia syndrome (TTS) associated with COVID-19 adenoviral vector vaccines Vaxzevria and Jcovden. Little is known about how such measures impacted on national vaccination strategies and how they influenced decision-making processes of policy-makers and experts. The aim of this study was to evaluate the impact of regulatory actions for Vaxzevria and Jcovden on national vaccination strategies following the EMA's 2021 review on safety measures on TTS. Methods: A grey literature review was performed to gather information on EMA's actions as well as changes to national vaccination strategies in Denmark, Greece, Latvia, the Netherlands, Portugal and Slovenia. Semi-structured interviews were held with experts who had either advisory or decision roles in national vaccination programmes to contextualise the results of the grey literature review and discuss their experiences. Interviews were coded and analysed on national levels. Results: EMA made various adaptations to product information and released safety warnings and other regulatory communications for both vaccines relating to TTS risk. Countries varied widely in changes made to national vaccination policies. Interviews revealed that experts relied mainly on their professional networks and information sources, other than the EMA, to inform their recommendations and/or decision-making. Conclusion: EMA's regulatory actions were not the main source informing adaptations to national vaccination strategies. National decision-makers country reverted to their preferred sources. The use of varying sources explains some of the variations in the vaccination strategies.

Language:English
Keywords:regulatory measures, COVID-19, national vaccination programs, decision-making, risk communication, coronavirus
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:11 str.
Numbering:Vol. 18, no. 1, art. 2576620
PID:20.500.12556/RUL-175779 This link opens in a new window
UDC:614:616.98-036.21:578.834
ISSN on article:2052-3211
DOI:10.1080/20523211.2025.2576620 This link opens in a new window
COBISS.SI-ID:256240899 This link opens in a new window
Publication date in RUL:07.11.2025
Views:129
Downloads:40
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of pharmaceutical policy and practice
Shortened title:J. pharm. policy pract.
Publisher:Taylor & Francis
ISSN:2052-3211
COBISS.SI-ID:523229977 This link opens in a new window

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.

Secondary language

Language:Slovenian
Keywords:regulativni ukrepi, COVID-19, nacionalni programi cepljenja, odločanje, obveščanje o tveganjih, koronavirus, virusna cepiva, cepiva proti covidu-19

Projects

Funder:European Medicines Agency
Project number:EMA/2018/23/PE

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back